Skip to content

PIRET PHARMA

Active Private limited companyfounded 2022active for 4 yearsRue de Beaumont 147, 6030 CharleroiKBO/BCE: BE 0783.830.868

Lifetime

3 annual accounts with figures on one time axis
peak of €245,891 in 2023
€171,047▼ 5.9%
peak of €48,323 in 2024
€35,490▼ 26.6%
peak of €126,674 in 2025
€126,674▲ 38.9%
€548,539▼ 11.4%
peak of 1.1 FTE in 2023
1.1 FTEunchanged
Board2 names since 2022
2 directors and 1 other
Documentsfilings and deeds
27-08-202627 days late
2025abbreviated format
Result from €48,323 to €35,490Equity from €91,183 to €126,674Cash from €91,746 to €122,011

Key points

from the 2025 annual accounts

Turnover

≈ €800,000 estimated

The accounts state no turnover.

Debts

€548,539 81% of the balance sheet
Financial debts 53%Suppliers 7%Taxes and wages 3%Other 36%

Of this, €257,478 falls due within a year.

Filings

3 annual accounts 3 late
AprilJune31 JulyOctober202320242025

The 2024 accounts came in latest, 61 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 7,984 companies had the same profile as PIRET PHARMA has now. Each dot stands for 20 companies, two years later.

94.2%
were still trading
1.9%
stopped another way
3.6%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.3% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 7,984 companies, not a prediction for PIRET PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director,
  • 50 sharesdeed of 29-03-2022
  • 50 sharesdeed of 29-03-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0783830868
Incorporation Founding capital of €5,000, 100 shares · Founded by and · (director) and (director) appointed · published on 29-03-2022 · Gazette deed
First establishment Place du Perron 20, Charleroi
All 9 events

Comparable companies

same main activity, similar in size and age
Company
PIRET PHARMA Charleroi €675,213 €171,047 18.8% 1.1
PIRET-LESSIRE PHARMA Charleroi €574,336 €140,926 9.7% 1.3
PHARMA DE COCK Ingelmunster €587,807 €205,824 32.9% 1.1
APOTHEEK TONGEREN WEST Tongeren-Borgloon €575,431 €195,028 27.3% 1.4
Pharmacie de Fétinne Liège €558,769 €197,710 59.1% 1
PHARMEINSA Saint-Vith €757,173 €247,327 0.7% 1
De Maeyer Groot-Bijgaarden Dilbeek €479,884 €163,151 37.3% 1

These companies have the same main activity as PIRET PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €480,000 and €757,000, founded between 2020 and 2022.

Official details

Source: KBO
Status
Active since 25-03-2022Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.331.461.5146030 Charleroi, since 25-03-2022
Financial year end
31 December
Peppol
Reachable since 03-12-2025
Company details

Annual accounts 2025

€675,213▼ 5.0%
Employeeson 31-12-2025
2=
Filing
Filed on 27-08-2026
Financials

Insights on PIRET PHARMA

PIRET PHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €245,891 in 2023 to €171,047 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about PIRET PHARMA

What is the company number of PIRET PHARMA?
The company number of PIRET PHARMA is 0783.830.868. The VAT number is the same number with BE in front: BE 0783.830.868.
Where is PIRET PHARMA based?
The registered office is at Rue de Beaumont 147, 6030 Charleroi.Company details
What does PIRET PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of PIRET PHARMA?
PIRET PHARMA is a private limited company (BV).
When was PIRET PHARMA founded?
PIRET PHARMA was founded on 25-03-2022.
Is PIRET PHARMA still active?
Yes, PIRET PHARMA is an active enterprise in the KBO register.
How many employees does PIRET PHARMA have?
PIRET PHARMA had an average of 1.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of PIRET PHARMA?
The turnover in financial year 2025 is about €800,000. This figure is estimated from the gross margin of €171,047 and 43 comparable companies (NACE 477). It probably lies between €530,000 and €1.7m.
Is PIRET PHARMA profitable?
In financial year 2025, PIRET PHARMA made a profit of €35,490.
Where can I find the annual accounts of PIRET PHARMA?
PIRET PHARMA filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PIRET PHARMA due?
PIRET PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.